Diamyd Medical and partners receive VINNOVA funding of SEK 40 million for prevention of autoimmune diseases
STOCKHOLM, September 23, 2021 / PRNewswire / – Swedish government innovation agency VINNOVA provides 40 million Swedish kronor in funding a sustainable precision healthcare innovation environment to be led by Diamyd Medical. The project aims to develop and evaluate new algorithms based on artificial intelligence (AI) for precision preventive medical treatments for type 1 diabetes and other autoimmune diseases. The innovation community also mainly includes AI AB, Lund University, Sahlgrenska University Hospital, National Diabetes Registry and Leading Healthcare Foundation. Diamyd Medical’s share of the five-year grant is approximately 18 million Swedish kronor.
“This is an incredibly exciting and potentially revolutionary project in type 1 diabetes and autoimmune diseases,” says Ulf Hannelius, CEO of Diamyd Medical. “We know that the autoimmune attack on the body’s insulin-producing cells begins years before the patient is diagnosed with type 1 diabetes – and we know we have a great opportunity to turn the tide. disease with, among others, the Diabetes vaccine Diamyd. If we can develop new algorithms that can more accurately predict who is at risk and when diagnosis is expected to occur, we have the potential to make individualized preventive health care a reality. reality.
The innovation community ASSET (AI for Sustainable Prevention of Autoimmunity in the Society) will develop and evaluate new algorithms based on AI to be able to assess the individual risk of developing type 1 diabetes. The data to be exploited come from the ” TEDDY (The Environmental Determinants of Diabetes in the Young) cohort study, Diamyd Medical clinical trials with Diamyd® and the National Diabetes Registry. Other autoimmune diseases strongly linked to type 1 diabetes, in particular celiac disease (gluten intolerance) and autoimmune thyroiditis (inflammatory disease of the thyroid gland), will also be studied. The prediction algorithm will be evaluated in two smaller prevention trials where people at high risk for type 1 diabetes will be treated preventively with the Diamyd diabetes vaccine.®. In parallel, ASSET will study the implications / effects of the health system in terms of the organizational, economic and legal preconditions and consequences of applying the suggested precision health approach in the Swedish health system. The aim is to proactively tackle obstacles that can slow down the implementation and diffusion of innovations in the health system.
MainlyAI is a research and technology company providing new AI and ML methods for prediction, knowledge extraction, KPI monitoring and decision support. The company has successfully applied cutting-edge privacy-preserving data and knowledge federation methods to accelerate and democratize the introduction of AI technologies into industries. MainlyAI’s approach is centered on a platform as a service with an API providing a database of knowledge and information, and services that simplify data / information access and adoption of technology. AI for business.
On Lund University
Lund The university was founded in 1666 and is consistently ranked among the top 100 universities in the world. The University has approximately 44,000 students and over 8,000 staff members in Lund, Helsingborg and Malmö. The unique disciplinary range encourages cross-border collaborations both within academia and with society at large, creating ideal conditions for scientific breakthroughs and innovations. The University has a distinct international profile, with partner universities in nearly 70 countries. The CRC at Lund University in Malmö is a leading biomedical research center integrated into the University Hospital of Skåne. The Center for Autoimmunity and Prevention has research projects suitable for preclinical and clinical studies initiated by researchers in type 1 diabetes, celiac disease, autoimmune thyroid disease and narcolepsy.
About Sahlgrenska University Hospital
Sahlgrenska University Hospital (SUH) is one of the from Sweden largest university hospitals, in close proximity to all areas of teaching and research. SUH operates as the county hospital for residents of the Gothenburg in addition to being a driving force for the development of healthcare and medicine in the Västra Götaland region. The SUH Pediatric Diabetes Clinic is an EU / SWEET reference center with a high level of documented care. The number of patients is the second highest in Sweden with over 550 patients regularly visiting the outpatient clinic. Diabetes research focuses on clinical interventions in the treatment of diabetes, particularly in early childhood disease, and on the early detection of complications. The pediatric diabetes clinical team is heavily involved in the regional, national and international development of guidelines and structures for pediatric diabetes care.
About the Swedish National Diabetes Registry
The Swedish National Diabetes Registry (NDR) was established in 1996 with the overall aim of reducing morbidity and mortality, as well as maximizing the cost-effectiveness of diabetes care. It is the largest diabetes registry in the world. The non-submission report is an instrument to facilitate such monitoring and to disseminate the results in an accessible, transparent, comparable and timely manner. The register is both a results repository and an educational tool to improve local quality assessment efforts. The registry helps focus on national quality indicators while tracking various process measures that are important at the local level. The NDR also promotes and facilitates the influence and participation of patients in their care and treatment.
About the Leading Healthcare Foundation
The Leading Health Care Foundation (LHC) is an independent academic think tank working to promote dialogue on how to improve health care and social services. The LHC conducts research and disseminates knowledge relevant to the organization, governance, management and transformation of health systems. The LHC has an extensive academic network and an active partner network which currently consists of around 30 organizations from different parts of the industry. In collaboration with partners, the LHC conducts research projects, seminars and workshops on challenges and opportunities in the field of health and social services. LHC aims to provide an arena where different organizations and interests can come together and exchange views with a common goal in mind: to create value for patients and for society. Since 2009, the LHC has been an independent, non-profit foundation. The LHC is mainly funded by research contracts and annual grants from partner organizations.
About Diamyd Medical
Diamyd Medical develops precision medicine therapies for type 1 diabetes. The Diamyd diabetes vaccine® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results were shown in a large group of genetically predefined patients in a large-scale meta-analysis as well as in the European Phase IIb trial of the Company DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults. with recently diagnosed type 1 diabetes. Preparations for a confirmatory phase III trial in the United States and Europe are underway, to begin recruiting patients later in 2021. A vaccine manufacturing plant is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical is also developing GABA-based investigational drug Remygen® as therapy for the regeneration of endogenous insulin production and for improving the hormonal response to hypoglycemia. Remygen on the initiative of an investigator® a clinical trial in patients living with type 1 diabetes for more than five years is underway at Uppsala University Hospital. Diamyd Medical is a major shareholder of the stem cell company NextCell Pharma AB.
Diamyd Medical’s B share is traded on the Nasdaq First North Growth Market under the symbol DMYD B. FNCA Sweden AB is the authorized adviser of the company; phone: +46 8-528 00 399, e-mail: [email protected]
For more information, please contact:
Ulf Hannelius, President and CEO
Telephone: +46 736 35 42 41
E-mail: [email protected]
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/diamyd-medical-ab/r/diamyd-medical-and-partners-are-awarded-sek-40-million-in-vinnova-funding-for-the-prevention-of- automatic, c3420805
The following files are available for download:
SOURCE Diamyd Medical AB